Some things will always remain unfettered. Like sunshine and air, like suffering and joy, like sharing and caring. Some things will never recognize the confines of space and time. Like human endeavour and enterprise, like the desire to touch life. At Morepen, we are taking our expertise and experience in Wellness to new countries and new people with an increasing focus on global exports. And in doing so, our spirit of caring is crossing boundaries.
India's oil and gas sector is dominated by state-owned companies. India is the third largest energy consumer globally and its energy demand is expected to double by 2035. Oil consumption has expanded at a CAGR of 4.78% during 2007-2017 to reach 4.69 million barrels per day in 2017, with India retaining its spot as the third largest oil consumer. Gas consumption has increased at a CAGR of 3.40% between 2007-2017 and demand is projected to further rise significantly by 2040. The country increasingly relies on imports to meet its growing demand for oil and gas.
The document analyzes and summarizes the status and development of China's franchise market from 2000 to 2009. It highlights the growth trends of major franchise enterprises in industries like retail, catering, apparel, and budget hotels. The Chinese franchise market is consolidating, expanding to lower-tier cities, and seeing more domestic franchise brands emerge in the next 5-10 years.
This is a very good presentation on Indian Pharmaceutical sector prepared by India Brand Equity Fund ( IBEF ) working under Commerce Ministry, Govt of India. A very good effort is made to cover all aspects of Indian pharma.They could have included ABLE also.
Industry CEOs can consider to use this ppt in overseas presentations.
Brief Report on the Indian Pharmaceutical Industry - 2011david_singer
The document summarizes the pharmaceutical industry in India. It provides an overview of the industry, noting that it is highly fragmented with over 20,000 registered units and is a $4.5 billion industry growing annually by 8-9%. It also profiles some of the largest pharmaceutical companies in India, including Ranbaxy, Dr. Reddy's Laboratories, and Cipla, and discusses their operations, market shares, and R&D investments. The industry is a major exporter of generic drugs and has a competitive advantage due to its skilled workforce and cost-effective production capabilities.
Indian Pharma market is predominantly a branded generic market. How does this auger for the industry per se, how is it then placed to grow going in the future. This brief presentation attempts to throw some light on the said topic
The Indian pharmaceutical sector is estimated to reach $100 billion by 2025, accounting for 10% of the global pharmaceutical industry by volume. It currently accounts for 20% of global generic exports. The sector is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion. By 2020, India will be among the top 3 pharmaceutical markets by growth and 6th largest globally. The government has implemented policies and initiatives like 'PharmaVision 2020' to make India a global pharmaceutical leader and improve affordability and availability of medicines.
India's oil and gas sector is dominated by state-owned companies. India is the third largest energy consumer globally and its energy demand is expected to double by 2035. Oil consumption has expanded at a CAGR of 4.78% during 2007-2017 to reach 4.69 million barrels per day in 2017, with India retaining its spot as the third largest oil consumer. Gas consumption has increased at a CAGR of 3.40% between 2007-2017 and demand is projected to further rise significantly by 2040. The country increasingly relies on imports to meet its growing demand for oil and gas.
The document analyzes and summarizes the status and development of China's franchise market from 2000 to 2009. It highlights the growth trends of major franchise enterprises in industries like retail, catering, apparel, and budget hotels. The Chinese franchise market is consolidating, expanding to lower-tier cities, and seeing more domestic franchise brands emerge in the next 5-10 years.
This is a very good presentation on Indian Pharmaceutical sector prepared by India Brand Equity Fund ( IBEF ) working under Commerce Ministry, Govt of India. A very good effort is made to cover all aspects of Indian pharma.They could have included ABLE also.
Industry CEOs can consider to use this ppt in overseas presentations.
Brief Report on the Indian Pharmaceutical Industry - 2011david_singer
The document summarizes the pharmaceutical industry in India. It provides an overview of the industry, noting that it is highly fragmented with over 20,000 registered units and is a $4.5 billion industry growing annually by 8-9%. It also profiles some of the largest pharmaceutical companies in India, including Ranbaxy, Dr. Reddy's Laboratories, and Cipla, and discusses their operations, market shares, and R&D investments. The industry is a major exporter of generic drugs and has a competitive advantage due to its skilled workforce and cost-effective production capabilities.
Indian Pharma market is predominantly a branded generic market. How does this auger for the industry per se, how is it then placed to grow going in the future. This brief presentation attempts to throw some light on the said topic
The Indian pharmaceutical sector is estimated to reach $100 billion by 2025, accounting for 10% of the global pharmaceutical industry by volume. It currently accounts for 20% of global generic exports. The sector is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion. By 2020, India will be among the top 3 pharmaceutical markets by growth and 6th largest globally. The government has implemented policies and initiatives like 'PharmaVision 2020' to make India a global pharmaceutical leader and improve affordability and availability of medicines.
The document provides an overview of the pharmaceutical industry in India. Some key points:
1. The Indian pharmaceutical industry is expected to grow to $100 billion by 2025 from $27.57 billion in 2016, expanding at a CAGR of 12.89% between 2015-2020.
2. India accounts for 20% of global exports in generics drugs, with exports standing at $16.84 billion in 2016-17 and projected to reach $20 billion by 2020.
3. The domestic generics drugs market was valued at $26.1 billion in 2016 and has significant potential for further growth.
Indian Pharmaceutical Market Overview 2013 by Nitesh BheleNitesh Bhele
The document summarizes the Indian pharmaceutical market in 2013. It highlights that the Indian market was valued at around $10 billion and was expected to grow double digits in the next five years. The generic drugs market was estimated to make up around 90% of the prescription drug market by 2016. It also provides an overview of the key segments of the Indian pharmaceutical market, the largest global companies, top therapeutic classes and products, as well as government initiatives to support industry growth.
Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015–20 to reach US$ 55 billion, making it among the fastest growing industries. India exports 20% of global exports in generics, with pharmaceutical exports at US$ 16.8 billion in 2016-17 and projected to reach US$ 20 billion by 2020. The generics market stood at US$ 26.1 billion in 2016 with high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in FY 2015
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs and exports were $16.8 billion in 2016-17, expected to reach $20 billion by 2020.
- The generics market in India stands at $26.1 billion in 2016 and has strong growth potential.
- Major segments of the pharmaceutical industry in India include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow to $55 billion by 2020, expanding at a CAGR of 12.89% from 2015-2020.
- India accounts for 20% of global exports in generics, with pharmaceutical exports at $16.84 billion in 2016-17, expected to reach $20 billion by 2020.
- The biotech industry in India is also growing rapidly, estimated to increase from $11 billion in 2015-16 to $100 billion by 2024-25.
The document provides an overview of the Indian pharmaceutical industry. It notes that the industry is expected to grow to $100 billion by 2025, making India one of the top global markets. Currently valued at $27.57 billion, the industry is growing at 12.89% annually and exports over $16 billion worth of drugs globally each year. The generics market and biotech sector also have strong growth potential. The industry benefits from low production costs, a large skilled workforce, and government support for further development.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs. Exports stood at $16.84 billion in 2016-17 and are expected to reach $20 billion by 2020.
- The domestic pharmaceutical market was worth $27.57 billion in 2016 and is estimated to have grown 7.4% to $29.61 billion in 2017. The market is expected to continue growing rapidly over the next few years.
The document provides an overview of the Indian pharmaceutical industry, including its history, growth, market structure, competition, exports and imports, and the effects of foreign investment. Some key points:
- The industry has grown significantly since its early years and now accounts for 8% of global pharmaceutical production.
- Major players include Ranbaxy, Dr. Reddy's Laboratories, Sun Pharmaceuticals, and AurobindoPharma.
- Exports have shown strong growth and now contribute around half of revenue for top companies. The US and Europe are major export markets.
- Foreign investment has impacted areas like new drug development, manufacturing standards, and marketing skills. Mauritius is a significant source of foreign
Changing trends in Indian Pharmaceutical IndustryRishang Deoras
The document summarizes the evolution of the Indian pharmaceutical industry through five phases from the pre-1970s to the present. It began with foreign company domination and a lack of organized Indian companies (Phase I). The government then gained control and capped drug prices, allowing local companies to emerge (Phase II). Indian companies then focused on bulk drug manufacturing and exports (Phase III) before experiencing rapid domestic and international market expansion (Phase IV). The industry is now focused on innovation, research, and adapting to changing patent laws (Phase V). The document also outlines India's competitive advantages in low-cost, high-quality drug production and its significant cost advantages over the US. It discusses the impact of TRIPS and new drug pricing policies on
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India is a major global player in pharmaceuticals, accounting for around 3% of the global industry. The market is expected to grow to $55 billion by 2020 and $100 billion by 2025.
- India has a large generics market and is a major exporter, accounting for 20% of global exports. Exports were $16.84 billion in 2016-17 and are projected to reach $20 billion by 2020.
- Key segments of the market include generics, Active Pharmaceutical Ingredients, Contract Research and Manufacturing Services, and biosimilars. Anti-infectives represent the largest segment dome
Dabur reported a modest 15% year-over-year growth in revenue to Rs. 972.8 crores driven by steady volume growth across segments. Earnings grew 15.4% to Rs. 160.4 crores, in line with estimates. Operating margins expanded slightly by 17 basis points despite a contraction in gross margins, helped by lower advertising spend. Segment-wise, consumer care grew 15.1% while consumer health and the international business grew at higher rates. The company maintained its guidance for steady volume growth and margins in the coming years.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at US$33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Major export destinations include North America, Africa, and the European Union. Indian companies are increasing R&D spending to develop new drugs and looking for growth opportunities in global markets through exports and acquisitions.
This document discusses how the global healthcare profit pool will shift between 2010 and 2020. It predicts that the total profit pool will grow at 4% annually from $520 billion to $740 billion over this period. However, profitability will decline for most players as the sources of growth and margins change significantly between sectors and regions. Innovative pharmaceutical and medical technology companies will see much slower growth and declining margins. In contrast, providers of healthcare delivery and lower-margin sectors like generics will capture a larger share of profits. To remain competitive, companies will need to develop new business models focused on improving healthcare delivery and outcomes rather than just generating more products and procedures.
Pharmaceutical Industry: Key Issues in Growth in Pakistan & International MarketRizwan Raheem Ahmed
Pakistan has a very vibrant and forward-looking Pharma Industry. At the time of independence in 1947, there was hardly any pharma industry in the country. Today Pakistan has about 400 pharmaceutical manufacturing units including those operated by 25 multinationals present in the country. The Pakistan Pharmaceutical Industry meets around 70% of the country's demand of Finished Medicine. The domestic pharma market, in term of share market is almost evenly divided between the Nationals and the Multinationals (Ahmed & Saeed, 2012).
The National pharma industry has shown a progressive growth over the years, particularly over the last one decade. The industry has invested substantially to upgrade itself in the last few years and today the majority industry is following Good Manufacturing Practices (GMP), in accordance with the domestic as well as international Guidance. Currently the industry has the capacity to manufacture a variety of product ranging from simple pills to sophisticated Biotech, Oncology and Value Added Generic compounds (Aamir & Zaman, 2011).
Although Pakistan 's pharmaceutical and healthcare sectors are expanding and evolving rapidly, about half the population has no access to modern medicines. Clearly this presents an opportunity, but much more work needs to be done by the government and industry's stakeholders. The value of pharmaceuticals sold in 2007 exceeded US$1.4bn, which equates to per capita consumption of less than US$ 10 per year and value of medicines sold is expected to exceed US$2.3 B by 2012 (Ahmed et al., 2011).
Covid -19 has a huge impact on market this year. Many companies are dissolved, many are in debt. this document shows the impacts and measures taken by sectors and companies to overcome the outbreak.
This document provides a summary of Magnit's FY 2010 IFRS results. It begins with background information on Magnit and a disclaimer. It then outlines Magnit's history and growth strategy, which involves further expanding its convenience store operations, rolling out additional hypermarkets, and improving efficiency. Financial highlights are provided showing Magnit's strong performance and growth in key metrics like sales, gross margin and net income.
Indian pharmaceutical industry By Big Pharma JobsBig Pharma Jobs
The Indian pharmaceutical industry has grown substantially over the past few decades and is expected to continue growing. It has expanded from $0.3 billion in 1980 to $12 billion currently, and is projected to reach $1.5 trillion globally by 2020. The industry faces issues such as patent cliffs wiping out revenues, high R&D costs, and increasing regulatory pressures. However, India has a large, fragmented industry with low-cost production, a dominant position in generic drugs, and is a major exporter and provider of affordable medicines to its population and globally. Key local and international players operate in the growing Indian market.
Impact of Covid 19 on selected sectors of Indian stock marketSonaliKhadaria
The research investigates the impact of the lockdown period caused by the COVID-19 to the stock market of India. The study examines the extent of the influence of the lockdown on the Indian stock market and whether the market reaction would be the same in pre- and post-lockdown period caused by COVID-19 and also what are the ways company chosen to fight against it.
This document provides an overview of the branded generics pharmaceutical market in India and the company Mankind Pharma. It summarizes Mankind's growth and success in the Indian market through organic expansion of its field force and market share, growing its portfolio of branded generic drugs, and expanding globally to over 12 countries. Key metrics shown include its rising domestic market share and rankings over time, high growth rates compared to industry averages, and leadership in key therapeutic segments like anti-diabetics and cardiac drugs.
Magnit reported its 9M 2012 results. It operates 5,523 convenience stores, 105 hypermarkets, and 480 cosmetics stores across Russia. The company aims to further expand its convenience store and hypermarket operations while improving efficiency and profitability. Key strategies include opening 1,000 new convenience stores and 50-55 hypermarkets in 2012, increasing private label products, and optimizing labor productivity.
Este documento describe los roles de Social Media Manager, E-Commerce Manager y Community Manager. Un Social Media Manager es responsable de diseñar estrategias de redes sociales y realizar estudios de mercado. Un E-Commerce Manager gestiona las ventas en línea y promueve la marca digitalmente. Un Community Manager crea contenido atractivo y mantiene una comunidad leal de seguidores en línea.
Tecnologia de la información y comunicación y su uso por los niños y los adol...sayra De los santos
Este documento analiza el uso de la tecnología de la información y la comunicación por parte de los niños y adolescentes. Explica que los niños han integrado perfectamente estas tecnologías en sus vidas principalmente para fines de comunicación y entretenimiento. También describe los niveles de equipamiento tecnológico en los hogares españoles y el tiempo que los niños dedican a cada medio. Finalmente, analiza factores como el control parental, las adicciones a Internet y el impacto del teléfono móvil en la socialización y privacidad de los
The document provides an overview of the pharmaceutical industry in India. Some key points:
1. The Indian pharmaceutical industry is expected to grow to $100 billion by 2025 from $27.57 billion in 2016, expanding at a CAGR of 12.89% between 2015-2020.
2. India accounts for 20% of global exports in generics drugs, with exports standing at $16.84 billion in 2016-17 and projected to reach $20 billion by 2020.
3. The domestic generics drugs market was valued at $26.1 billion in 2016 and has significant potential for further growth.
Indian Pharmaceutical Market Overview 2013 by Nitesh BheleNitesh Bhele
The document summarizes the Indian pharmaceutical market in 2013. It highlights that the Indian market was valued at around $10 billion and was expected to grow double digits in the next five years. The generic drugs market was estimated to make up around 90% of the prescription drug market by 2016. It also provides an overview of the key segments of the Indian pharmaceutical market, the largest global companies, top therapeutic classes and products, as well as government initiatives to support industry growth.
Indian pharmaceutical sector accounts for about 2.4% of the global pharmaceutical industry in value terms and 10% in volume terms. The country's pharmaceutical industry is expected to expand at a CAGR of 12.89% over 2015–20 to reach US$ 55 billion, making it among the fastest growing industries. India exports 20% of global exports in generics, with pharmaceutical exports at US$ 16.8 billion in 2016-17 and projected to reach US$ 20 billion by 2020. The generics market stood at US$ 26.1 billion in 2016 with high potential for growth. By 2024-25, India's biotech industry is estimated to increase to US$ 100 billion from US$ 11 billion in FY 2015
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs and exports were $16.8 billion in 2016-17, expected to reach $20 billion by 2020.
- The generics market in India stands at $26.1 billion in 2016 and has strong growth potential.
- Major segments of the pharmaceutical industry in India include active pharmaceutical ingredients, formulations, biosimilars, and contract research and manufacturing.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow to $55 billion by 2020, expanding at a CAGR of 12.89% from 2015-2020.
- India accounts for 20% of global exports in generics, with pharmaceutical exports at $16.84 billion in 2016-17, expected to reach $20 billion by 2020.
- The biotech industry in India is also growing rapidly, estimated to increase from $11 billion in 2015-16 to $100 billion by 2024-25.
The document provides an overview of the Indian pharmaceutical industry. It notes that the industry is expected to grow to $100 billion by 2025, making India one of the top global markets. Currently valued at $27.57 billion, the industry is growing at 12.89% annually and exports over $16 billion worth of drugs globally each year. The generics market and biotech sector also have strong growth potential. The industry benefits from low production costs, a large skilled workforce, and government support for further development.
The document provides an overview of the pharmaceutical industry in India. Some key points:
- The Indian pharmaceutical industry is expected to grow at a CAGR of 12.89% until 2020 to reach $55 billion in size.
- India accounts for 20% of global exports in generics drugs. Exports stood at $16.84 billion in 2016-17 and are expected to reach $20 billion by 2020.
- The domestic pharmaceutical market was worth $27.57 billion in 2016 and is estimated to have grown 7.4% to $29.61 billion in 2017. The market is expected to continue growing rapidly over the next few years.
The document provides an overview of the Indian pharmaceutical industry, including its history, growth, market structure, competition, exports and imports, and the effects of foreign investment. Some key points:
- The industry has grown significantly since its early years and now accounts for 8% of global pharmaceutical production.
- Major players include Ranbaxy, Dr. Reddy's Laboratories, Sun Pharmaceuticals, and AurobindoPharma.
- Exports have shown strong growth and now contribute around half of revenue for top companies. The US and Europe are major export markets.
- Foreign investment has impacted areas like new drug development, manufacturing standards, and marketing skills. Mauritius is a significant source of foreign
Changing trends in Indian Pharmaceutical IndustryRishang Deoras
The document summarizes the evolution of the Indian pharmaceutical industry through five phases from the pre-1970s to the present. It began with foreign company domination and a lack of organized Indian companies (Phase I). The government then gained control and capped drug prices, allowing local companies to emerge (Phase II). Indian companies then focused on bulk drug manufacturing and exports (Phase III) before experiencing rapid domestic and international market expansion (Phase IV). The industry is now focused on innovation, research, and adapting to changing patent laws (Phase V). The document also outlines India's competitive advantages in low-cost, high-quality drug production and its significant cost advantages over the US. It discusses the impact of TRIPS and new drug pricing policies on
The document provides an overview of the pharmaceutical industry in India. Some key points:
- India is a major global player in pharmaceuticals, accounting for around 3% of the global industry. The market is expected to grow to $55 billion by 2020 and $100 billion by 2025.
- India has a large generics market and is a major exporter, accounting for 20% of global exports. Exports were $16.84 billion in 2016-17 and are projected to reach $20 billion by 2020.
- Key segments of the market include generics, Active Pharmaceutical Ingredients, Contract Research and Manufacturing Services, and biosimilars. Anti-infectives represent the largest segment dome
Dabur reported a modest 15% year-over-year growth in revenue to Rs. 972.8 crores driven by steady volume growth across segments. Earnings grew 15.4% to Rs. 160.4 crores, in line with estimates. Operating margins expanded slightly by 17 basis points despite a contraction in gross margins, helped by lower advertising spend. Segment-wise, consumer care grew 15.1% while consumer health and the international business grew at higher rates. The company maintained its guidance for steady volume growth and margins in the coming years.
Indian pharmaceutical industry supplies over 50% of global demand for various vaccines and generic drugs. The pharmaceutical sector was valued at US$33 billion in 2017 and is expected to grow at 15% annually. India accounts for 20% of global exports in generics. Major export destinations include North America, Africa, and the European Union. Indian companies are increasing R&D spending to develop new drugs and looking for growth opportunities in global markets through exports and acquisitions.
This document discusses how the global healthcare profit pool will shift between 2010 and 2020. It predicts that the total profit pool will grow at 4% annually from $520 billion to $740 billion over this period. However, profitability will decline for most players as the sources of growth and margins change significantly between sectors and regions. Innovative pharmaceutical and medical technology companies will see much slower growth and declining margins. In contrast, providers of healthcare delivery and lower-margin sectors like generics will capture a larger share of profits. To remain competitive, companies will need to develop new business models focused on improving healthcare delivery and outcomes rather than just generating more products and procedures.
Pharmaceutical Industry: Key Issues in Growth in Pakistan & International MarketRizwan Raheem Ahmed
Pakistan has a very vibrant and forward-looking Pharma Industry. At the time of independence in 1947, there was hardly any pharma industry in the country. Today Pakistan has about 400 pharmaceutical manufacturing units including those operated by 25 multinationals present in the country. The Pakistan Pharmaceutical Industry meets around 70% of the country's demand of Finished Medicine. The domestic pharma market, in term of share market is almost evenly divided between the Nationals and the Multinationals (Ahmed & Saeed, 2012).
The National pharma industry has shown a progressive growth over the years, particularly over the last one decade. The industry has invested substantially to upgrade itself in the last few years and today the majority industry is following Good Manufacturing Practices (GMP), in accordance with the domestic as well as international Guidance. Currently the industry has the capacity to manufacture a variety of product ranging from simple pills to sophisticated Biotech, Oncology and Value Added Generic compounds (Aamir & Zaman, 2011).
Although Pakistan 's pharmaceutical and healthcare sectors are expanding and evolving rapidly, about half the population has no access to modern medicines. Clearly this presents an opportunity, but much more work needs to be done by the government and industry's stakeholders. The value of pharmaceuticals sold in 2007 exceeded US$1.4bn, which equates to per capita consumption of less than US$ 10 per year and value of medicines sold is expected to exceed US$2.3 B by 2012 (Ahmed et al., 2011).
Covid -19 has a huge impact on market this year. Many companies are dissolved, many are in debt. this document shows the impacts and measures taken by sectors and companies to overcome the outbreak.
This document provides a summary of Magnit's FY 2010 IFRS results. It begins with background information on Magnit and a disclaimer. It then outlines Magnit's history and growth strategy, which involves further expanding its convenience store operations, rolling out additional hypermarkets, and improving efficiency. Financial highlights are provided showing Magnit's strong performance and growth in key metrics like sales, gross margin and net income.
Indian pharmaceutical industry By Big Pharma JobsBig Pharma Jobs
The Indian pharmaceutical industry has grown substantially over the past few decades and is expected to continue growing. It has expanded from $0.3 billion in 1980 to $12 billion currently, and is projected to reach $1.5 trillion globally by 2020. The industry faces issues such as patent cliffs wiping out revenues, high R&D costs, and increasing regulatory pressures. However, India has a large, fragmented industry with low-cost production, a dominant position in generic drugs, and is a major exporter and provider of affordable medicines to its population and globally. Key local and international players operate in the growing Indian market.
Impact of Covid 19 on selected sectors of Indian stock marketSonaliKhadaria
The research investigates the impact of the lockdown period caused by the COVID-19 to the stock market of India. The study examines the extent of the influence of the lockdown on the Indian stock market and whether the market reaction would be the same in pre- and post-lockdown period caused by COVID-19 and also what are the ways company chosen to fight against it.
This document provides an overview of the branded generics pharmaceutical market in India and the company Mankind Pharma. It summarizes Mankind's growth and success in the Indian market through organic expansion of its field force and market share, growing its portfolio of branded generic drugs, and expanding globally to over 12 countries. Key metrics shown include its rising domestic market share and rankings over time, high growth rates compared to industry averages, and leadership in key therapeutic segments like anti-diabetics and cardiac drugs.
Magnit reported its 9M 2012 results. It operates 5,523 convenience stores, 105 hypermarkets, and 480 cosmetics stores across Russia. The company aims to further expand its convenience store and hypermarket operations while improving efficiency and profitability. Key strategies include opening 1,000 new convenience stores and 50-55 hypermarkets in 2012, increasing private label products, and optimizing labor productivity.
Este documento describe los roles de Social Media Manager, E-Commerce Manager y Community Manager. Un Social Media Manager es responsable de diseñar estrategias de redes sociales y realizar estudios de mercado. Un E-Commerce Manager gestiona las ventas en línea y promueve la marca digitalmente. Un Community Manager crea contenido atractivo y mantiene una comunidad leal de seguidores en línea.
Tecnologia de la información y comunicación y su uso por los niños y los adol...sayra De los santos
Este documento analiza el uso de la tecnología de la información y la comunicación por parte de los niños y adolescentes. Explica que los niños han integrado perfectamente estas tecnologías en sus vidas principalmente para fines de comunicación y entretenimiento. También describe los niveles de equipamiento tecnológico en los hogares españoles y el tiempo que los niños dedican a cada medio. Finalmente, analiza factores como el control parental, las adicciones a Internet y el impacto del teléfono móvil en la socialización y privacidad de los
This document contains a summary of Siva Raghavendra kumar's qualifications and experience working as an IBM Tivoli Storage Manager consultant. He has over 2 years of experience administering TSM servers and clients on Windows and UNIX platforms. His roles include configuring backups, managing storage pools and libraries, troubleshooting issues, and reporting on backup status. He is currently leading the US region on a project for Bayer that involves maintaining their global data center infrastructure.
Este documento describe los roles y responsabilidades de varios administradores de redes sociales y comercio electrónico. Un Social Media Manager es responsable de diseñar estrategias de marketing en redes sociales, un E-Commerce Manager gestiona las ventas en línea, y un Community Manager mantiene una comunidad leal de seguidores en línea.
Flor de Maria Tello Patiño presenta sobre aprendizaje autónomo, enfatizando que no se trata simplemente de estudiar mucho por uno mismo, sino de aprender de una manera más profunda y significativa.
This document lists some currently popular rock artists such as Twenty One Pilots, Imagine Dragons, Coldplay, Green Day, and Red Hot Chili Peppers. It also notes that article topics could include a new album, real life issues, interviews, how the artists started their careers, and gaining fame through the internet.
El documento habla sobre el aprendizaje autónomo. Explica que se refiere a la capacidad de aprender por uno mismo desarrollando habilidades en diferentes entornos de aprendizaje. Describe estrategias cognitivas y metacognitivas que permiten tener un buen aprendizaje autónomo. Las estrategias cognitivas incluyen revisar material de estudio, mientras que las metacognitivas implican comprender los pasos a seguir y planear el desarrollo. Ventajas de aprendizaje autónomo son desarrollar autodiscipl
Suresh Undley has over 12 years of experience in UI/UX design. He specializes in designing compelling user experiences for software, websites, and mobile apps. Some of his skills include wireframing, prototyping, visual design, and user research. He has worked on projects for clients in various industries such as banking, insurance, and e-commerce.
This was disclosed by Mr. Sushil Suri, Chairman and Managing Director, Morepen Laboratories Ltd. after the company’s board meeting, which discussed and took on record the fourth quarter and annual results of the company for the financial year 2015-16. “After attaining leadership in Loratadine, by being world’s largest generic supplier of the bulk drug, Morepen Laboratories Ltd. has attained a leadership in its second molecule -Montelukast,” he pointed out.
Lupin Pharmaceutical is an Indian pharmaceutical company with multiple branches located throughout India that specialize in different areas of production such as APIs, formulations, and herbal products. The company has experienced significant growth in recent years, with net sales increasing 38% from 2005 to 2006 due to successful product launches in the US market as well as strong domestic performance. Lupin also significantly increased investments in R&D and intellectual property.
IPCA Laboratories Ltd is an Indian pharmaceutical company with a presence in domestic branded formulations, global branded/generic formulations, and APIs. The document recommends IPCA as an Alpha/Alpha+ stock and outlines factors that will drive its growth over the next 3 years, including: 1) 16-18% growth in domestic formulations business; 2) Increased sales from US generics business once issues at its Indore facility are resolved; 3) Scaling up its institutional anti-malaria business to Rs. 1000 crores. IPCA is well positioned in the anti-malarial space due to its API manufacturing and participation in programs like AMFm that aim to increase global access to affordable ACT treatments.
This document provides an analysis of the external environment of Incepta Pharmaceuticals Ltd using several frameworks. It conducts a PESTEL analysis to examine the political, economic, social, technological, environmental and legal factors affecting the company. It also uses Porter's Five Forces model to analyze the competitive environment in the pharmaceutical industry. The balanced scorecard framework is applied to evaluate Incepta's performance. Finally, Incepta's vision, mission and strategic management process are described.
This document provides an analysis of the external environment of Incepta Pharmaceuticals Ltd using several frameworks. It conducts a PESTEL analysis to examine the political, economic, social, technological, environmental and legal factors affecting the company. It also uses Porter's Five Forces model to analyze the competitive landscape. The balanced scorecard framework is applied to evaluate Incepta's performance. Finally, the strategic management model is outlined to identify the company's current situation and strategic goals.
The pharmaceutical industry in India is the third largest in the world by volume. It has grown significantly since the 1960s and now holds a market share of $14 billion in the US. Exports of pharmaceutical products from India have grown at a compound annual rate of 21.25% between 2006-07 and 2008-09. Ranbaxy Laboratories is a major Indian pharmaceutical company with global sales of over $1 billion in 2006. It has manufacturing facilities in several countries and markets drugs in over 125 countries. The Indian pharmaceutical industry is poised for continued growth and increasing global market share in the coming years.
Morepen inks pact with vésale pharma to boost presence in rs 1000morepen
NEW DELHI: Indian pharmaceutical firm Morepen LaboratoriesBSE -0.24 % Ltd, listed on the Bombay Stock Exchange, has inked an exclusive agreement to market and distribute Belgian probiotics player Vesale Pharma International's major brands in the gastroenterology segment—a deal it hopes will help it strengthen its presence in India's growing probiotics market.
Aarti Drugs (ADL) is a part of well known Aarti group of industries. The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also manufactures formulations through its wholly-owned subsidiary- Pinnacle Life Science Private Limited.
The company has a long standing track record in the bulk drugs industry and has been supplying products to demanding domestic and international customers.
Working Capital Management on Cadila Healthcare Limited.Moin Panja
This document provides background information on the history and development of the Indian pharmaceutical industry. It discusses how the industry grew after the 1970 Patent Act which removed composition patents from drugs and shortened process patents. This allowed Indian companies to enter the market and become a major global supplier of generic drugs. It also outlines key statistics on the current size and growth of the Indian pharmaceutical industry, which is now the 3rd largest producer globally and poised to become a $20 billion industry by 2015. The document notes that while many players are small-medium enterprises, foreign companies still control a large portion of the domestic market in India.
Zydus Group was founded in 1952 and restructured in 1995 into Cadila Healthcare and Cadila Pharmaceuticals. Cadila Healthcare later adopted the name Zydus Group. Zydus Group has achieved strong growth in global markets like the US, Europe, Japan, and emerging markets. In the US, Zydus is among the top 20 fastest growing generic companies and focuses on difficult to make products. Financially, Zydus has grown significantly from 2005-2006 to 2009-2010 in total income, EBIT, EPS, and R&D expenditures.
With the help of Dr. Morepen Sushil suri, Morepen Labs' standalone net profit...Morepen
Morepen Laboratories has posted strong growth of 179 per cent in standalone net profit during the fourth quarter ended March 2017 to Rs. 7.72 crore from Rs. 2.77 crore in the corresponding period of last year. Its net sales increased by 15.7 per cent to Rs. 142.95 crore from Rs. 123.59 crore. Interest cost declined significantly to Rs. 0.66 crore from Rs. 2.68 crore.
The document provides information on trends in the Indian pharmaceutical sector. It notes that Indian pharmaceutical companies are increasing spending on research and development to develop new drugs. Exports of pharmaceutical products from India have grown significantly in recent years and are expected to exceed USD15 billion in 2015, as Indian companies have a strong presence in the generics market. The top four pharmaceutical firms in India by revenue - Dr. Reddy's, Lupin, Cipla and Aurobindo - account for over 20% of the domestic market share. Anti-infective drugs represent the largest segment of the Indian pharmaceutical market. Exports and domestic sales have increased the size of the Indian pharmaceutical market to USD36.7 billion in 2016.
Biocon’s nine months revenue continues to deliver steady growth in fy13Biocon
Biocon, an Indian biopharmaceutical company, reported a 23% year-over-year increase in 9-month revenues to Rs 1,889 Crores, with growth across its biopharma, research services, and branded formulations verticals; the company also received approval for its novel monoclonal antibody Itolizumab and advanced several pipeline programs including biosimilar trials.
Performance analysis of working capital management of “pharmaceuticals industry”Fayshal Hossan Miazy
The document appears to be a term paper submitted by a group of students to their course teacher Khairul Alom at Southeast University. It discusses performance analysis of working capital management of five pharmaceutical companies in Bangladesh - Square Pharmaceuticals Ltd., Ibn Sina Pharmaceuticals Ltd., Ambee Pharmaceuticals Ltd., Beximco Pharmaceuticals Ltd., and Renata Pharmaceuticals Ltd. The paper includes an introduction to the pharmaceutical sector in Bangladesh, historical background of the five companies, methodology used involving data collection and analysis, and a theoretical literature review. Ratio analysis and time series analysis is performed for the five companies and a comparative analysis is presented.
SeQuent Scientific announced its Q3 FY20 financial results, with revenues up 17% to Rs. 3,164 million and EBITDA up 36.4% to Rs. 484 million. For 9M FY20, revenues were up 16% to Rs. 8,787 million and EBITDA grew 34.9% to Rs. 1,247 million. The company expects to meet its full-year guidance of high-teen revenue growth and over 200 bps expansion in EBITDA margins.
Morepen labs profit up | Under Dynamic Leadership of Sushil Suri CBImorepen
New Delhi, May 1 (UNI) Morepen Laboratories Limited has reported a 179 per cent rise in its net profit at Rs 7.73-crore and 17.4 per cent rise in its net sales revenue at Rs 141-crore in the fourth quarter (Q4) of fiscal 2016-17.
The net profit and the net sales revenue stood at Rs 2.77-crore and Rs 119.77-crore in the corresponding quarter of the fiscal 2015-16.
Chemicals Global Market Report provides strategists, marketers and senior management with the critical information they need to assess the global chemical sector.
The total value of the chemicals sector globally in 2014 was $4,406 billion. Related to a world population of more than 7 billion in 2014 this equates to about $629.4 per person per annum.
The chemical industry is one of the largest manufacturing industries in the world. It manufactures a variety of chemical products by processing raw materials such as air, water, natural gas, oil, metals and minerals.
Hemas is a diversified conglomerate with LKR 38 billion in annual revenues. It operates businesses in consumer goods, healthcare, transportation, and leisure. In the fiscal year 2015/16, Hemas saw 16.9% revenue growth and 17.5% growth in operating profits. The consumer and healthcare sectors performed strongly, with the consumer sector growing revenues by 20.2% and healthcare by 16%. Hemas has leading market positions and brands in key sectors such as pharmaceutical distribution, hospitals, and consumer products.
The document provides information on the pharmaceutical industry in India. Some key points:
- India accounts for 20% of global pharmaceutical exports and the domestic market is expected to reach $55 billion by 2020, growing at a CAGR of 12.89% from 2015-2020.
- The generics market is the largest segment in India, accounting for 70% of the domestic market. India supplies 20% of global generic medicines by volume.
- Key growth drivers for the industry include low production costs, growing demand, policy support from the government, and a large/diversified product portfolio. The industry attracted 5% of total FDI into India from 2000-2016.
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
Fexofenadine is sold under the brand name Allegra.
It is a selective peripheral H1 blocker. It is classified as a second-generation antihistamine because it is less able to pass the blood–brain barrier and causes lesser sedation, as compared to first-generation antihistamines.
It is on the World Health Organization's List of Essential Medicines. Fexofenadine has been manufactured in generic form since 2011.
Phosphorus, is intensely sensitive to ‘other worlds’ and lacks the personal boundaries at every level. A Phosphorus personality is susceptible to all external impressions; light, sound, odour, touch, electrical changes, etc. Just like a match, he is easily excitable, anxious, fears being alone at twilight, ghosts, about future. Desires sympathy and has the tendency to kiss everyone who comes near him. An insane person with the exaggerated idea of one’s own importance.
Emotion-Focused Couples Therapy - Marital and Family Therapy and Counselling ...PsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
Congestive Heart failure is caused by low cardiac output and high sympathetic discharge. Diuretics reduce preload, ACE inhibitors lower afterload, beta blockers reduce sympathetic activity, and digitalis has inotropic effects. Newer medications target vasodilation and myosin activation to improve heart efficiency while lowering energy requirements. Combination therapy, following an assessment of cardiac function and volume status, is the most effective strategy to heart failure care.
CLASSIFICATION OF H1 ANTIHISTAMINICS-
FIRST GENERATION ANTIHISTAMINICS-
1)HIGHLY SEDATIVE-DIPHENHYDRAMINE,DIMENHYDRINATE,PROMETHAZINE,HYDROXYZINE 2)MODERATELY SEDATIVE- PHENARIMINE,CYPROHEPTADINE, MECLIZINE,CINNARIZINE
3)MILD SEDATIVE-CHLORPHENIRAMINE,DEXCHLORPHENIRAMINE
TRIPROLIDINE,CLEMASTINE
SECOND GENERATION ANTIHISTAMINICS-FEXOFENADINE,
LORATADINE,DESLORATADINE,CETIRIZINE,LEVOCETIRIZINE,
AZELASTINE,MIZOLASTINE,EBASTINE,RUPATADINE. Mechanism of action of 2nd generation antihistaminics-
These drugs competitively antagonize actions of
histamine at the H1 receptors.
Pharmacological actions-
Antagonism of histamine-The H1 antagonists effectively block histamine induced bronchoconstriction, contraction of intestinal and other smooth muscle and triple response especially wheal, flare and itch. Constriction of larger blood vessel by histamine is also antagonized.
2) Antiallergic actions-Many manifestations of immediate hypersensitivity (type I reactions)are suppressed. Urticaria, itching and angioedema are well controlled.3) CNS action-The older antihistamines produce variable degree of CNS depression.But in case of 2nd gen antihistaminics there is less CNS depressant property as these cross BBB to significantly lesser extent.
4) Anticholinergic action- many H1 blockers
in addition antagonize muscarinic actions of ACh. BUT IN 2ND gen histaminics there is Higher H1 selectivitiy : no anticholinergic side effects
A congenital heart defect is a problem with the structure of the heart that a child is born with.
Some congenital heart defects in children are simple and don't need treatment. Others are more complex. The child may need several surgeries done over a period of several years.
1.
A a 0
Morepen Laboratories Scores No. 1 Position Globally for its Bulk
Drug Montelukast
Business Wire | Mumbai | ,
Morepen Laboratories Scores No. 1 Position Globally for its Bulk Drug Montelukast
+ -
Business Wire India
Morepen Laboratories Ltd. has established a leadership position for its anti-asthmatic bulk drug Montelukast in the global market.
As per the latest report published by a global research firm - QYR Research, Morepen is the No.1 supplier globally in terms of
total quantity sold, followed by Mylan and TAPI (Teva) who appear on the second and third position respectively.
Morepen’s global sales for Montelukast Sodium stood at 16240 kgs in the calender year 2015, resulting in a market share of 23
per cent (approx.) compared to Mylan’s and Teva’s 12 per cent each, the report claims.
This was disclosed by Mr. Sushil Suri, Chairman and Managing Director,
Morepen Laboratories Ltd. after the company’s board meeting, which discussed
and took on record the fourth quarter and annual results of the company for the
financial year 2015-16. “After attaining leadership in Loratadine, by being world’s
largest generic supplier of the bulk drug, Morepen Laboratories Ltd. has attained a
leadership in its second molecule -Montelukast,” he pointed out.
Morepen Laboratories Ltd. has reported an over 25-fold increase in its net profit for
the financial year ended March 31, 2016. The net profit increased from Rs. 58 lakhs
in FY 2014 -15 to Rs. 15.78 crore in FY 2015-16. The total operating revenue in FY
2015-16 stood at Rs. 452.46 crore as against Rs. 370.26 crore in the previous
fiscal, registering a growth of 22.20 per cent.
For the fourth quarter ended March 31, 2016, net profit rose to Rs. 2.77 crore on a
total operating revenue of Rs. 123.59 crore as compared to a loss of Rs. 3.72 crore
on a total operating revenue of Rs. 85.36 crore in the corresponding quarter of the
previous fiscal.
Morepen’s EBIDTA increased by 36.30 per cent in fiscal 2015-16 at Rs. 65.38 crore and the cash surplus (i.e. EBDTA) rose by 40
per cent at Rs. 54.96 crore compared to Rs. 47.95 crore and Rs. 39.31 crore respectively, in the previous fiscal.
“Enhanced focus on cost reduction and adoption of innovative processes resulted in this remarkable turnaround,
putting the company back on the profit trajectory,” Mr. Suri said.
Q4 marked excellent performance in all business segments particularly bulk drugs (API) which has grown by more than 50%,
while Home Diagnostics and Finished Dosages segments also outperformed and registered a remarkable growth of 35% and
40% respectively adding to the outstanding quarterly performance.
Total revenues from the bulk drug Montelukast in Q4 grew by more than 90% at Rs. 25.71 crore. Thus, Montelukast registered
the highest growth amongst bulk drugs followed by Loratadine and Atorvastatin, which grew by 20% and 37% respectively,
over Q4 last year. In the FY 2015-16, total revenue from Montelukast crossed Rs. 74 crores and is likely to cross Rs. 100 crore
mark in fiscal 2016-17.
Exports: With strategic international positioning, the company’s export turnover has crossed Rs. 200 crores in FY 2015-16,
registering a growth of 32 per cent. The exports turnover is expected to grow by 25% Year-on-Year and is likely to cross Rs. 250
crore in fiscal 2016-17.
In the home health category, Morepen’s Diagnostics division grew by 23% Year-on-year. The company cemented its leadership in
Blood Glucose Monitors market by registering 41% growth in fiscal 2015-16 with a top line of Rs.33.38 crores. It sold more than
30 million test strips in fiscal 2015-16. Looking at increasing incidence of diabetic cases in India, this segment offers great
X
converted by Web2PDFConvert.com
2. Comments Login
There are no comments to display. Be the first one to comment!
opportunity for growth in the coming years.
About Morepen Laboratories Ltd.
Morepen Laboratories Ltd. is a 30-year old pharmaceutical and healthcare products company. The company went public in the
year 1993 and is currently listed at both the Bombay Stock Exchange as well as the National Stock Exchange.
Morepen is engaged in the manufacturing and sale of APIs/ Bulk Drugs, Home Diagnostics, Formulations and OTC products. The
company’s state-of-the-art manufacturing facility at Baddi (Himachal Pradesh) comprises a scientifically integrated complex of 10
plants, each with a specific product profile. The USFDA approved plant at Masulkhana is for manufacture of Loratadine, an anti-
allergy drug – internationally known as Claritin. The new blockbuster drug Montelukast is also manufactured at this FDA
approved site. The large and spread out manufacturing facility at Baddi manufactures latest and much in demand products like
Atorvastatin, Rosuvastatin, Sitagliptin and others for regulated markets of USA and also for non-regulated markets across the
globe.
Morepen markets over 100 branded formulations under six major therapeutic segments in the domestic market. It has WHO GMP
facilities for manufacturing of Formulations. The company’s manufacturing facilities are backed by a strong dedicated team of
research and development (R&D) professionals who ensure stringent quality standards. In Home - Diagnostics business, Morepen
has a formidable presence in Blood Glucose Monitors and Blood Pressure Monitors, which are imported by the company for sale
in the domestic market. The company’s OTC brands are being promoted under its wholly owned subsidiary Dr. Morepen Limited.
Dr. Morepen’s famous OTC product line, including Burnol, Lemolate, Sat-Isabgol, Fever-X, Pain-X and others, has a significant
presence in the domestic market.
Photo Caption: Mr. Sushil Suri, Chairman and Managing Director, Morepen Laboratories Ltd
Tags Business/ Finance Advertising PR & marketing
Advertisements
Get your free IIFL Demat & Trading A/c now...Click here
Get the most detailed result analysis on the web - Real Fast!
Actionable & Award-Winning Research on 500 Listed Indian Companies.
IT Newsletter - September 19 to 23, 2016
Telecom Newsletter - September 19 to 23, 2016
Merger and Acquisition Round up - September 19 to 23, 2016
Retail Newsletter - September 19 to 23, 2016
Real Estate Newsletter - September 19 to 23, 2016
Pharmaceutical Newsletter - September 19 to 23, 2016
Infrastructure Newsletter - September 19 to 23, 2016
Oil and Gas Newsletter - September 19 to 23, 2016
Banking and Finance Newsletter - September 19 to 23, 2016
Automobile Newsletter - September 19 to 23, 2016
Industry Newsletter
converted by Web2PDFConvert.com
3. CONNECT WITH IIFL: facebook | twitter Commodity Ideas Stock Ideas
IIFL Live Corporate News RSS
More
CUSTOMER CARE
Technology/Trader Terminal related queries
022-41514151
Equity/Currency & Commodity/Spot
022-40071000
Gold/NCD/NBFC/Insurance and NPS
180030001155 / 022-61064444
Login To Trade | Open a Trading Account
Investor Relations | About IIFL | We're Hiring | Contact Us
Thursday, 29 September 2016 14:58 IST
IIFL GROUP
Trade Premia Wealth Flame Property Solutions Business Partners Finance
PRODUCTS & SERVICES
Desktop Widget Research Mortgages Insurance Wealth Management Discretionary PMS TT Edge Business loans
TRADING DOCUMENTATION
Download TT TT Login TT Demo Account Details Fund Transfer Helpdesk Download Forms Document & Info
USEFUL LINKS
BSE NSE MCX NCDEX Bullion Desk Forex Factory Exchange Holidays
OFFBEAT
converted by Web2PDFConvert.com
雅虎竞拍
煤炉代买
paypay商城
乐天二手
日本亚马逊
乐天新品
ZOZOTOWN
